Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. Issue 8 (14th May 2021)

• Record Type: Journal Article
• Authors: van der Aart‐van der Beek, Annemarie B.; Cherney, David; Laverman, Gozewijn D.; Stefansson, Bergur; van Raalte, Daniel H.; Hoogenberg, Klaas; Reyner, Daniel; Li, Qiang; Di Tanna, Gian Luca; Greasley, Peter J.; Heerspink, Hiddo J. L.
• Is Part Of: Diabetes, obesity & metabolism. Volume 23:Issue 8(2021)
• Page Start: 1961
• Page End: 1967
• Publication Date: 2021-05-14
• Subjects: dapagliflozin -- SGLT2 inhibitor -- type 2 diabetes -- diabetic nephropathy; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14411
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: High protein intake may increase intraglomerular pressure through dilation of the afferent arteriole. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors may reduce intraglomerular pressure through activation of tubuloglomerular feedback. Given these opposing effects, we assessed whether the effect of dapagliflozin on glomerular filtration rate (GFR) and urinary albumin‐to‐creatinine ratio (UACR) was modified by estimated dietary protein intake using data from three separate randomized controlled trials (DELIGHT, IMPROVE and DIAMOND). The median protein intake was 58.4, 63.6 and 90.0 g/d, respectively. In the DELIGHT trial (n = 233), dapagliflozin compared to placebo caused an acute and reversible dip in GFR of 2.1 and 2.2 mL/min/1.73 m 2, and reduced UACR by 20.5% and 28.4% in participants with high and low protein intake, respectively. Similarly, in IMPROVE (n = 30) and DIAMOND (n = 53), the effect of dapagliflozin on GFR and UACR was comparable in participants with high and low protein intake (all P for interaction > 0.40). This post hoc, exploratory analysis of three clinical trials suggests that dietary protein intake does not modify the individual response of clinical kidney variables to dapagliflozin.